Asiapac: The moving Center of Gravity of the Pharma Industry
- Vast geography home to 3 Billion people
- Economy of $20 Trillion with China, Japan, India, Australia & Korean among the Top 15 economies
- Total Pharma market size of $242 Bill in 2011 & expected to be $420 Bill by 2020
- Healthy growth of 9% in the region and 14% without Japan. Pure generic growth well over 15%
- APAC will contribute 51% of value growth to world market by 2020
- Harmonized ACTD regulatory guidelines across ASEAN markets
- Healthcare reforms/insurance just starting in many markets
PHILIPPINES: A SNAPSHOT vis-à-vis GLOBAL MARKET
USD 4.4 B 0.4% of global market
Prescription driven products market
Overfocus on pricing
Essentially an OOP market
Formulation exports is negligible business
Sourcing and import dependent
Taiwan
US$ 4.5 Bill
Reimbursement market driven by hospital’s buying power
Not crowded, longer gestation but attractive margins
Vietnam
US$ 2.6 Bill
Growing at 13 %
Market split into volume products and newer products.
Brazil
- 8th Largest market in the world
- Estimated to be US$ 26 .5 Billion
- 35 % of Latin American market , Growing at 11 %
- Generic penetration about 23 % and growing at 18 %
- Out of 540 companies 90 are in generics
- Top 5 TAs /Opportunities -in Cardio ( Angiotensin II Antagonist & Lipid regulators ), Antiulcerants , Oral Diabetes, Obesity and Muscle relaxants.
- Initially licensing or contract manufacturing
- Need investment in ANVISA approval and PE/BEs at approved CROs
- Prices higher than even many Asian markets
South Africa
- Total market US$ 4.2 Bill growing at 12 .6 %
- Privately supplied worth ZAR 19.5 Bill ( 80 % ) & State funded worth ZAR 4.7 Bill ( 20 % )
- Private market generic penetration is 58 %
- NHI bill tabled in parliament
- Process of marketing being reviewed.
- SAHPRA severely under-resourced with delays of 5 years in approvals
- Over 75 % imports but still very attractive markets for niche products.
